Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod

Targeting sphingosine-1-phosphate pathway with orally available immune-modulatory fingolimod (Gilenya™) therapy ameliorates relapsing–remitting multiple sclerosis (RRMS) by decreasing relapse rate as shown in FREEDOMS and TRANSFORMS. Fingolimod has also been shown to be superior to interferon-beta t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jong-Mi, Han, May H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446999/
https://www.ncbi.nlm.nih.gov/pubmed/26056436
http://dx.doi.org/10.2147/PPA.S57354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446999/
https://www.ncbi.nlm.nih.gov/pubmed/26056436
http://dx.doi.org/10.2147/PPA.S57354

Ejemplares similares